DOCSLIB.ORG

Harmful Polypharmacy Medicine Reviewarthur D

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Harmful Polypharmacy Medicine Reviewarthur D OHSU InernalHarmful polypharmacy Medicine ReviewArthur D. Hayward, MD, MBA OHSU InernalHarmful polyp Medicineharmacy ReviewArthur D. Hayward, MD, MBA OHSU InernalI have nothing Medicine to disclose. Review Case Study: DoesOHSU Verda need pravastatin? Inernal Medicine Review Outline (And, But, Therefore)OHSU • Our era of medicine is dominated by new and powerful drugs • InernalBut drug overuse risks harm Medicine • We must use drugsReview judiciously and cautiously. The EnlightenedOHSU Era of Drugs • Previously untreatable diseases are now treatable, and • FormerlyInernal hospitalized are now Medicinetreatable as outpatients, and • Longevity has increased, and • Some costs have decreased. (?) • But… Review But…Do we overemphasizeOHSU drugs? • Commercialization and its imperatives* • Medicalization of normal states and conditions • MisleadingInernal claims and marginal Medicine benefits • Increased risk of adverse effects1 * • Rising costs* • Neglect of non-drugReview treatment2 * • Public Disillusionment 1Qato DM. JAMA Intern Med. Changes in Prescription… 2016 Apr;176(4):473-82. 2Ioannidis. Comparative Effectiveness of Exercise…BMJ 2013;347:f5577 Commercialization Increase revenue (shareholderOHSU value) • Invent new drugs • Sell more current drugs • Increase demand • Expand the market Inernal• Add indications (antipsychotics) Medicine • Extend treatment (statins, opioids) • Ensure Insurance coverage (Medicare, private insurers) • Penetrate more of the existing market (statins) • Advertising and promotion1 • Direct to consumers ($2.1 to 9.6B) • To opinion leaders and prescribers ($15.6 to 20.3B) • Help generate and promoteReview guidelines • Lower prices?? • Outcompete • Extend patents • Raise prices 1Schwartz LM, Woloshin S. Medical Marketing… 1997 to 2016. JAMA. 2019;321(1):80-96 Promotion/ Advocacy/OHSU Hype • The term “miracle drug” came into use around 1944 to refer to a substance “that elicits a dramatic response in a patient’s condition”. (Merriam Webster Dictionary) • InInernal 2015 in one 4-day span 94 articlesMedicine from 64 distinct news outlets used “miracle” or synonyms like “break-through” or “game changer” referring to 36 specific new oncology drugs, half not yet approved by the FDA and severalReview not trialed in humans. Abola MV, Prasad V. Research Letter. JAMA Oncol. 2016:2(1);139-141 Changes in Medical Marketing Costs 1997 -2016 OHSU Inernal Medicine Review Rising costs of drugsOHSU • In 2016 the US spent $3,337 billion on national health expenditures and $329 billion on prescription drugs1. •InernalCMS projects spending for retailMedicine prescription drugs will be the fastest growth health category over the next decade2. Review 1Hartman, M et al. National Health Care Spending…. Health Affairs 37(1):150-160. Jan 2018 2Cuckler G et al. National Health Expenditure…Health Affairs 37(3); March 2018. New Drug ApprovalsOHSU Drug sales Pharma Inernal Medicine Experts Prescribers and ReviewAdvocates FDA Approval Podcast: Vinay Prasad Drug Dissemination DrugOHSU sales Pharma $$ $$ Inernal Medicine PrescribersReview Experts Coverage, Guidelines Adverse Drug EffectsOHSU (ADEs) • Pre-approval Phase Three trials may not detect infrequent ADEs. • Interactions may be unpredictable, multiple. • ADEsInernal can be undetected/ under Medicine-reported in clinical practice. • Prescribing patterns often do not change despite known risks. • Anticholinergics and antipsychotics in patients with dementia • Mistaking ADEs as new problems to be treated risks creating the prescribing cascade.Review The Prescribing Cascade OHSU Inernal Medicine Review Do we neglect nonOHSU-drug treatment? Inernal Medicine Review Ioanidis J. BMJ 2013;347:f5577 doi: 10.1136/bmj.f5577 (Published 1 October 2013) Polypharmacy in Preventive Cardiology1 OHSU Inernal Medicine Review 1J Am Coll Cardiol 2015;66:1273 European Association of Preventive Cardiology Exercise training recommended for Type II diabetics with CV diseaseOHSU • Target dysglycemia, dyslipidemia, arterial hypertension, obesity, reduced cardiovascular fitness • ImproveInernal insulin sensitivity, lipid profile, vascular Medicine reactivity, CV fitness, (inflammation?) • Mounting evidence (200+ references) • => Prescribe exercise training • Review How-to recommendations based on individual patient profiles. https://doi.org/10.1177/2047487318820420 (Euro J of Prev Cardiology Jan. 14, 2019) Therefore…?? OHSU A. Scrutinize literature carefully and skeptically. B. Consider drug alternatives1. C. InernalUse safer drugs2. Medicine D. Investigate possible adverse effects in your patients. E. Consider time-to-benefit vs longevity when prescribing. F. Deprescribe? Review 1 Trauer JM, Cunnington D. CBT for Chronic Insomnia… Ann Intern Med. 2016 Jan 19;164(2):134-5. 2Hanlon JT, Semla TP, Schmader KE. J Am Geriatr Soc. Alternative Medications… 2015 Dec;63(12):e8-e18. Scrutinize Clinical Trials Carefully 1. Doublecheck fundingOHSU sources and disclosures. 2. Consider methodology a. Note Exclusions. I. By age InernalII. By co-morbidities Medicine b. Is statistical significance clinically meaningful? 3. Ask whether findings have been reproduced in subsequent studies. 4. Consider misconductReview including falsification of data1. 1Seife C. Research misconduct identified by the US Food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature. JAMA Intern Med. 2015;175(4):567-577. doi:10.1001/jamainternmed.2014.7774 Last Observation Carried Forward OHSUMethodology Inernal Medicine Cognitive Dropouts with LOCF function Review Dropout Measure Time Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomized clinical trials. BMJ. 2005 Aug 6;331(7512):321–7. “Statistical Error Type 3” The statisticalOHSU B difference in A Inernaloutcome A… Medicine…is less than meaningful clinical Review benefit B Control Intervention See Lin JS, O’Connor E, et al. “Screening for Cognitive Impairment…”Ann Intern Med. 2013;159(9):601-612. Failures of Replication OHSU The Decline Effect Ioannidis Reviewed 49 high impact treatment or prevention studies 1990 - 2003 - 5 found no benefit Inernal MedicineOf 44 studies claiming benefit… - 11 not repeated - 7 contradicted - 7 found less efficacy => 14 of 33 (42%) of positive Review studies not confirmed Therefore…Deprescribe?OHSU Inernal• Yes? (benefits) Medicine • Why Reviewnot?? (obstacles) Benefits Reduce OHSU • Pill Burden • confusion • risks of potential adverse and of under-recognized Inernaldrug effects Medicine • paperwork and tasks of drug reconciliation • costs of care • nursing burdenReview Increase • Use of non-drug treatment • therapeutic alliance Obstacles to DeprescribingOHSU • Profiling and guidelines • Reversing decisions by other prescribers Inernal• Self-contradicting previousMedicine decisions • Time constraints • Patient choice…some of the time • TreatmentReview imperative Why Don’t (VA) PCPsOHSU Deprescribe? Survey results: Lack of awareness Inernal(39% not aware tight glucose control Medicine harms older adults) Fear of bad report card (42%) Fear of legal liability (25%) Not enough timeReview to discuss (30%) JAMA Intern Med. 2015;175(12):1994-1996. doi:10.1001/jamainternmed.2015.5950 OHSU Why and how we/ you deprescribe? Inernal Medicine Review How? • Solicit patientOHSU ideas and priorities • Go Step-by-Step • Offer alternatives Inernal• Get help* Medicine • Pharmacy specialists • Consult authoritative sources • Follow-upReview • Add “polypharmacy” to the problem list 2019 updated Beers Criteria OHSUFor adults 65 and older 1. Evidence scheme 2. Potentially inappropriate in most 3. Drug Disease issues Inernal Medicine4. Use with caution 5. Drug-Drug issues 6. Renal toxicity concern 7. Anticholinergics Review8. Meds removed 9. Meds added http//:deprescribing.org J Am Geriatr Soc. 2019 Jan 29. doi: 10.1111/jgs.15767. [Epub ahead of print] Non-Drug Treatment For Behavioral and Psychiatric Symptoms of DementiaOHSU (BPSD)1 Psychosocial practices Sensory • Validation therapy • Massage • Reminiscence therapy • Multi-sensory Inernal Medicine• Music therapy • Aromatherapy • Pet Stimulation • Meaningful activities • Bright light Structured care protocols Review• Bathing • Mouth care 1Scales, et al. Gerontologist, 2018, Vol. 58, No. S1, S88–S102 Individualized Nurse Non-Drug Treatment Interventions • For BPSD1 OHSU• Model desired behavior • Sensory • Massage • Avoid arguing • Multi-sensory • Aromatherapy • Engage in social interaction • Stimulation Inernal• Bright light • MedicineUse non verbal communication • Psychosocial practices • validation therapy • Identify and avoid triggers • reminiscence therapy • music therapy • Redirect • pet • meaningful activities Review• Recruit for “meaningful” activity • Structured care protocols • bathing • Provide live or inanimate pets • mouth care 1Scales, et al. Gerontologist, 2018, Vol. 58, No. S1, S88–S102 Case Study: DoesOHSU Verda need pravastatin? Inernal Medicine Review Michael A. Steinman; Joseph T. Hanlon Managing Medications in Clinically Complex Elders "There's Got to Be a Happy Medium" http://jama.ama-assn.org/cgi/content/full/304/14/1592 JAMA. 2010;304(14):1592-1601 (doi:10.1001/jama.2010.1482) Finding the balance between benefits and harms from statinsOHSU for primary prevention A “balance modeling” study Individualizes statin therapy recommendations Inernalby drug, patient age, sex, and calculated Medicine risk of ADEs and CV outcomes, including weighted preferences using these data
Load more

Recommended publications
  • Polypharmacy and the Senior Citizen: the Influence of Direct-To-Consumer Advertising
    2021;69:19-25 CLINICAL GETRIATRICS - ORIGINAL INVESTIGATION doi: 10.36150/2499-6564-447 Polypharmacy and the senior citizen: the influence of direct-to-consumer advertising Linda Sperling, DHA, MSN, RN1, Martine B. Fairbanks, Ed.D, MA, BS2 1 College of nursing, University of Phoenix, Arizona, USA; 2 College of doctoral studies, University of Phoenix, Arizona, USA Background. Polypharmacy, or taking five or more medications dai- ly, can lead to poor medication compliance and an increased risk for adverse drug-to-drug interactions that may eventually lead to death. The study was designed to explore the questions of how age, the re- lationship between the physician and patient, and television, radio, magazines and modern electronic technology, such as the Internet, affect patients’ understanding of their medical care. Two main areas addressed in this research study included the pharmaceutical indus- try’s influence on consumer decisions to ask a physician for a particular medication, and the prescribing practices of the physician. Methods. This qualitative phenomenological study began with pre- screening volunteer residents in a nursing home to discover poten- tial participants who met the criteria of using five or more medicines daily. We then interviewed 24 participants who met the criteria, using semi-structured interview questions. Results. Four core themes emerged from this study: professional trust, professional knowledge, communication deficit, and direct-to-consum- Received: April 30, 2020 er advertising. Participants reported trusting their doctors and taking Accepted: November 2, 2020 medications without question, but most knew why they were taking the Correspondence medications. Participants also reported seeing ads for medications, but Linda Sperling DHA, MSN, RN only one reported asking a physician to prescribe the medication.
    [Show full text]
  • Opioid Weaning Guidance Document Primary Care GENERAL CONSIDERATIONS: 1
    Opioid Weaning Guidance Document Primary Care GENERAL CONSIDERATIONS: 1. Determine if the goal is a dose reduction or complete discontinuation of agent(s). 2. Weans should occur gradually to minimize the risk of withdrawal symptoms. Weaning opioids may take 6 months or more depending on the total opioid dose and the individual patient’s response to the opioid wean. There is no need to rush this process as this may only cause more distress for the patient. 3. Optimize non-opioid pain management strategies. This link provides options for non-opioid strategies: https://www.cdc.gov/drugoverdose/pdf/alternative_treatments-a.pdf a. Recommend implementing one non-opioid agent at a time b. Evaluate and discontinue any agents that are ineffective c. Do not exceed maximum recommended doses or combine multiple agents from the same medication class d. Avoid use of benzodiazepines or any sedative hypnotic agents 4. Set expectations and functional goals with patient prior to initiation of the opioid wean. 5. Educate patient on the change in opioid tolerance over time during the opioid wean and risk for overdose if they resume their starting dose or a previously stable higher dose. Discuss/prescribe naloxone to minimize the risk of overdose. 6. Screen for and treat any untreated/under-treated depression. Depression may make the weaning process more challenging. MORPHINE EQUIVALENT DOSE CALCULATOR: 1. Link to calculator: http://www.agencymeddirectors.wa.gov/Calculator/DoseCalculator.htm 2. This calculator can be utilized to determine the current morphine equivalent dose your patient is receiving at baseline. If the goal is for opioid dose reduction, this calculator can also be used to determine your goal “ending” dose.
    [Show full text]
  • Qato Et Al, “Changes in Prescription and Over-The-Counter Medi
    Polypharmacy: time to get beyond numbers Invited commentary on: Qato et al, “Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011” and Jou et al, “Non-disclosure of complementary and alternative medicine (CAM) use to usual care providers: Findings from the 2012 National Health Interview Survey” Michael A. Steinman, MD Division of Geriatrics, University of California, San Francisco and the San Francisco VA Health Care System Word count: 1023 References: 7 Support: Supported by grants from the National Institute on Aging (K24-AG049057-01 and P30- AG044281) Acknowledgement / Disclosure: Dr. Steinman is a consultant for iodine.com, an internet start-up company. Corresponding author: Michael A. Steinman, MD 4150 Clement St, VA Box 181G San Francisco, CA 94121 [email protected] When I tell someone that I am a geriatrician, I often get the same response. I am told half- jokingly that the person needs my services. Then, I am regaled with a story of how the person’s older parent, grandparent, or spouse is prescribed an enormous number of medications, thinks they might be causing problems, and doesn’t know what to do about it. It is this view of polypharmacy that often dominates patients’, and increasingly clinicians’, experience of medication use. This skeptical perspective is largely justified. The number of medications a person uses is by far the strongest risk factor for medication-related problems. As the number of medications rises, adverse drug reactions become more common. Adherence worsens. Out-of-pocket costs rise.
    [Show full text]
  • Polypharmacy in the Elderly Educational Format Faculty Expertise Required Expertise in the Field of Study
    2019 AAFP FMX Needs Assessment Body System: Geriatrics Session Topic: Polypharmacy in the Elderly Educational Format Faculty Expertise Required Expertise in the field of study. Experience teaching in the field of study is desired. Preferred experience with audience Interactive REQUIRED response systems (ARS). Utilizing polling questions and Lecture engaging the learners in Q&A during the final 15 minutes of the session are required. Expertise teaching highly interactive, small group learning environments. Case-based, with experience developing and Problem- teaching case scenarios for simulation labs preferred. Other Based workshop-oriented designs may be accommodated. A typical OPTIONAL Learning PBL room is set for 50-100 participants, with 7-8 each per (PBL) round table. Please describe your interest and plan for teaching a PBL on your proposal form. Learning Objective(s) that will close Outcome Being Professional Practice Gap the gap and meet the need Measured Family physicians have 1. Use evidence-based criteria (e.g. Learners will gaps in knowledge and BEERS, STOPP, START) to submit written performance in evaluating evaluate for potentially adverse drug commitment to for potentially adverse drug events, among elderly patients change statements events, among elderly receiving multiple medications. on the session patients receiving multiple 2. Develop a systematic approach, evaluation, medications. including applicable REMS, to indicating how Family physicians have managing elderly patients with they plan to gaps in knowledge and
    [Show full text]
  • Polypharmacy & Deprescribing
    Lauren W. Mazzurco, DO Polypharmacy & Eastern Virginia Medical School Deprescribing [email protected] • I have no conflicts of interest to disclose Objectives • Describe the concept and impact of polypharmacy in older adults • Review the benefits of and potential barriers to deprescribing • Describe the process of rational deprescribing and demonstrate practical strategies of application to clinical scenarios https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Chronic-Conditions/Downloads/2012Chartbook.pdf Scope of the problem • 30% of patients >65 are prescribed >5 medications • ~1 in 5 medications in older adults may be inappropriate • Single most predictor of harm is # of medications 1. QatoDM,AlexanderGC,ContiRM,JohnsonM, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867-2878. 2. RougheadEE,AndersonB,GilbertAL. Potentially inappropriate prescribing among Australian veterans and war widows/widowers. Intern Med J. 2007;37(6):402-405 3. SteinmanMA,MiaoY,BoscardinWJ,Komaiko KD, Schwartz JB. Prescribing quality in older veterans: a multifocal approach. J Gen Intern Med. 2014;29(10):1379-1386 4. BudnitzDS,LovegroveMC,ShehabN,Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365 (21):2002-2012. Quality Value = Cost http://ihpi.umich.edu/news/older-americans-don’t-get-–-or-seek-–-enough-help-doctors-pharmacists-drug-costs- poll-finds. Accessed
    [Show full text]
  • Donzelot, Anti-Sociology
    An Anti- sociology JACQUES DONZELOT What was it that brought a man, one day, to stretch out on the analyst's couch to relate the details of his life? This is in a sense the question Michel Foucault raised in Madness and Civilization. In order to solve this problem, Foucault described an historical sequence of three centuries during which time the division separating madness and normality was plotted. The results of his investigation show psychoanalysis to be situated at the outermost point of the confinement trappings without foregoing its fundamental implications: "Freud did deliver the patient from the existence of the asylum within which his 'liberators' had alienated him; but he did not deliver him from what was essential in this existence ... he created the psychoanalytical situation in which, by an inspired short-circuit, alienation becomes disalienation, but the doctor as alienating figure remains the key to psychoanalysis." Yes, one could tell his life history on the couch. But in such conditions as this, Foucault wonders, what was to be understood? Foucault's impertinent conclusion directed at psychoanalysis was to please Gilles Deleuze and Felix Guattari to such an extent that they used it as a starting point for their own book and were able to systematically demolish psychoanalysis, construct a new theory of desire and, while they were at it, sketch the evolution of mankind from its origins to the present day. Each of these three aspects has been spoken about differently. The first aspect has been overly discussed, owing, it would D&G systematically seem, to the book's satirical demolish psychoanalysis, style aimed at ridiculing construct a new theory of psychoanalysis.
    [Show full text]
  • Medicalisation and Overdiagnosis: What Society Does to Medicine Wieteke Van Dijk*, Marjan J
    http://ijhpm.com Int J Health Policy Manag 2016, 5(11), 619–622 doi 10.15171/ijhpm.2016.121 Perspective Medicalisation and Overdiagnosis: What Society Does to Medicine Wieteke van Dijk*, Marjan J. Faber, Marit A.C. Tanke, Patrick P.T. Jeurissen, Gert P. Westert Abstract The concept of overdiagnosis is a dominant topic in medical literature and discussions. In research that Article History: targets overdiagnosis, medicalisation is often presented as the societal and individual burden of unnecessary Received: 2 May 2016 medical expansion. In this way, the focus lies on the influence of medicine on society, neglecting the possible Accepted: 23 August 2016 influence of society on medicine. In this perspective, we aim to provide a novel insight into the influence of ePublished: 31 August 2016 society and the societal context on medicine, in particularly with regard to medicalisation and overdiagnosis. Keywords: Medicalisation, Overdiagnosis, Society Copyright: © 2016 The Author(s); Published by Kerman University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http:// creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. *Correspondence to: Citation: van Dijk W, Faber MJ, Tanke MA, Jeurissen PP, Westert GP. Medicalisation and overdiagnosis: Wieteke van Dijk what society does to medicine. Int J Health Policy Manag. 2016;5(11):619–622. doi:10.15171/ijhpm.2016.121
    [Show full text]
  • The Problem of Power in ADHD: a Scoping Review
    The Problem of Power in ADHD: A Scoping Review Abraham Joseph Student number 211190287 Supervisor’s Name: Marina Morrow Advisor’s Name: Mary Wiktorowicz Supervisor’s Signature: Date Approved: June 10, 2020 Advisor’s Signature: Date Approved: June 10, 2020 A Research Paper submitted to the Graduate Program in Health in partial fulfillment of the requirements for the degree of: Master of Arts Graduate Program in Health York University Toronto, Ontario M3J 1P3 Defend date: June 10, 2020 1 Table of Contents Table of Contents 2 Abstract 4 Introduction 5 Background 6 Research Goals 12 Theoretical Frameworks/Methodology 14 Research Paradigm 14 Scoping Review Method 17 Search Strategy 18 Inclusion and Exclusion Criteria 20 Data Extraction and Analysis 20 Findings and Discussion 21 Nature of Evidence 21 Places of Psychiatric Power 23 Patterns of Psychiatric Power 26 Problems of Psychiatric Power 38 Strengths and Limitations 55 Implications and Conclusions 57 2 Acknowledgements 59 References 60 Appendix A – Database Search Flow Chart 71 Appendix B – Scoping Review Charting Summary 72 3 Abstract Attention deficit hyperactivity disorder (ADHD) has become the most diagnosed mental health issue for children worldwide. There are substantive critiques of the psychiatric basis for the conceptualization, diagnosis, and treatment that dominate the ADHD context. ADHD discourse and practice are largely influenced by the biomedical framework of mental health and illness. The pervasive, continued acceptance of the dominant biomedical ADHD narrative is problematic in terms of addressing mental health care needs as well as illustrative of the influence and power that psychiatry wields with respect to the ADHD landscape.
    [Show full text]
  • PREVENTING CHRONIC DISEASE PUBLIC HEALTH RESEARCH, PRACTICE, and POLICY Volume 17, E22 MARCH 2020
    PREVENTING CHRONIC DISEASE PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY Volume 17, E22 MARCH 2020 ORIGINAL RESEARCH Relationship Between Polypharmacy and Quality of Life Among People in 24 Countries Living With HIV Chinyere Okoli, MSc1; Patricia de los Rios, MSc2; Anton Eremin, MD3; Gary Brough, BA4; Benjamin Young, MD, PhD2; Duncan Short, PhD1 Accessible Version: www.cdc.gov/pcd/issues/2020/19_0359.htm Methods Suggested citation for this article:Okoli C, de los Rios P, We analyzed data for 2,112 adult PLHIV on antiretroviral therapy Eremin A, Brough G, Young B, Short D. Relationship Between (ART) in 24 countries who completed the 2019 Positive Perspect- Polypharmacy and Quality of Life Among People in 24 Countries ives survey. Polypharmacy was defined as taking 5 or more pills a Living With HIV. Prev Chronic Dis 2020;17:190359. DOI: https:// day or currently taking medications for 5 or more conditions. Out- doi.org/10.5888/pcd17.190359. comes were self-rated overall health, treatment satisfaction, and self-reported virologic control. New treatment concerns were is- sues not prioritized at ART initiation but now deemed paramount. PEER REVIEWED Data were analyzed with descriptive and multivariable statistics. Summary Results What is already known on this topic? Overall prevalence of polypharmacy was 42.1%. People reporting People living with HIV (PLHIV) have greater incidence of comorbidities and polypharmacy had significantly poorer health outcomes independ- higher prevalence of polypharmacy, most commonly defined as taking 5 or ent of existing comorbidities; their odds of treatment satisfaction, more medications concurrently, than the general population. optimal overall health, and virologic control were lower by 27.0% What is added by this study? (adjusted odds ratio [AOR] = 0.73; 95% CI, 0.59–0.91), 36.0% PLHIV reporting polypharmacy had significantly worse overall health out- (AOR = 0.64; 95% CI, 0.53–0.78), and 46.0% (AOR = 0.54, 95% comes, including significantly lower prevalence of self-reported virologic control and treatment satisfaction.
    [Show full text]
  • Opportunities to Increase Efficiency in Healthcare
    s REPORT 2020 | OCTOBER CONSULTING Maria Errea Rikard Althin Chris Skedgel Thomas Hofmarcher Bernarda Zamora Peter Lindgren Grace Hampson Graham Cookson OCTOBER 2020 Maria Errea Rikard Althin Office of Health Economics, The Swedish Institute for Health London Economics, Lund Chris Skedgel Thomas Hofmarcher Office of Health Economics, The Swedish Institute for Health London Economics, Lund Bernarda Zamora Peter Lindgren Office of Health Economics, The Swedish Institute for Health London Economics, Stockholm Grace Hampson Graham Cookson Office of Health Economics, Office of Health Economics, London London Please cite this report as: Errea, M., Skedgel, C., Zamora, B., Hampson, G., Althin, R., Hofmarcher, T., Lindgren, P. and Cookson, G., 2020. Opportunities to increase efficiency in healthcare. Consulting Report, London: Office of Health Economics. Available at https://www.ohe.org/publications/opportunities- increase-efficiency-healthcare Corresponding Author: Graham Cookson [email protected] Professor Graham Cookson Chief Executive, OHE Honorary Visiting Professor in Economics at City, University of London Tel +44 (0)207 747 1408 Email [email protected] ii Many of the studies OHE Consulting performs are proprietary and the results are not released publicly. Studies of interest to a wide audience, however, may be made available, in whole or in part, with the client’s permission. They may be published by OHE alone, jointly with the client, or externally in scholarly publications. Publication is at the client’s discretion. Studies published by OHE as OHE Consulting Reports are subject to internal quality assurance and undergo external review, usually by a member of OHE’s Editorial Panel. Any views expressed are those of the authors and do not necessarily reflect the views of OHE as an organisation.
    [Show full text]
  • FEBRUARY 2015 UCCOP Confidence Is a Sign of the Right Fit
    FEBRUARY 2015 ™ VOLUME 9, NUMBER 5 THE JOURNAL OF URGENT CARE MEDICINE® www.jucm.com The Official Publication of the UCAOA and UCCOP PUBLICATION BRAVEHEART A Confidence is a sign of the right fit. Urgent Care and Occupational Medicine are a great pair—that bring some colorful management dilemmas. AgilityUC is perfectly fitted for facilities that audaciously plan to excel at both. Streamline workflow demands. Flaunt your efficiency with a single billing system. One record per patient keeps PHI secure from workers' compensation data. Be cool, everything's covered. Learn more at nhsinc.com Software for Urgent Care nhsinc.com The Art of the Right Fit.™ © 201 Net Health. All Rights Reserved. LETTER FROM THE EDITOR-IN-CHIEF Evaluating Chest Pain in Urgent Care— “Catch 22 and the Three Bears”: Part 1 hat can Joseph Heller and Goldilocks way to the ED or gets into an accident, what will be your teach us about managing no-win situ- defense then? All patients presenting to an urgent care Wations in urgent care? As it turns out, if should have an evaluation that is reasonable for their clin- you look under the covers of Baby Bear’s ical condition. Ⅲ bed, you might find something meaning- Step 2: Determine whether the patient is stable or ful, perhaps even something that’s “just unstable. A patient with chest pain who is clinically unsta- right.” Take the classic no-win situation when patients present ble (e.g., the patient has altered responsiveness, has sig- to urgent care with chest pain. Without a definitive and reli- nificant bradycardia or hypoxia, has hypotension) should able test to guide our decision making, we are stuck with the trigger the initiation of emergency protocols regardless of ultimate “damned if you do, damned if you don’t” moment: underlying cause.
    [Show full text]
  • Mental Health in Ukraine
    2021 Yale Institute for Global Health Case Competition Mental Health in Ukraine 2021 Yale Institute for Global Health Case Competition Case Writing Team: Sina Reinhard (Chair), Yale School of Public Health Annan Dang, Yale School of Public Health Mitchelle Matesva, Yale School of Medicine Patricia Ryan-Krause, Yale School of Nursing (Faculty Advisor) Special thanks to Marie Brault for review of the case The scenarios, prompt, and vignettes of this case are based on existing initiatives, organizations, and individuals; however, details have been dramatized. Materials beyond the case scenario and prompt are meant to portray an accurate representation of global mental health and Ukraine’s burden of mental illness. The authors have provided facts and figures within the case and appendices to help teams. The data provided are derived from independent sources, may have been adapted for use in this case, and are clearly cited such that teams can verify or contest the findings within their recommendations if it is pertinent to do so. Introduction In January 2020, Ukraine was selected as a priority country for the World Health Organization’s (WHO) Special Initiative for Mental Health (2019-2023). Ukraine carries a high burden of mental illness with a particularly high prevalence of depression in comparison to other countries. Mental disorders are the country’s second leading cause of disability burden in terms of disability adjusted life years and are estimated to affect 30% of the population [100]. Since joining the initiative, Ukraine has experienced a renewed political commitment to mental health policy and service expansion combined with growing public interest in mental health issues.
    [Show full text]